Association of minor necrosis factor polymorphism with primary sclerosing cholangitis

Journal of Hepatology

Volumn 30, Issue 2, 1999, Pages 237-241

  Bernal, William ^a   Moloney, Manus ^a   Underhill, James ^a   Donaldson, Peter T ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

0301; Genetic associations; HLA; HLA B8; HLA DRB1; Primary sclerosing cholangitis; TNF2; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; HLA A1 ANTIGEN; HLA B8 ANTIGEN; HLA DR ANTIGEN; HLA-DRB1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ALLELE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; SCLEROSING CHOLANGITIS;

ADULT; ALLELES; CHOLANGITIS, SCLEROSING; FEMALE; HLA-A1 ANTIGEN; HLA-B8 ANTIGEN; HLA-DR ANTIGENS; HUMANS; MALE; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032587149     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80068-3     Document Type: Article

References (31)

1. Schrumpf E, Fausa O, Forre O, Dobloug J, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells associated with hepatobiliary disease. Scand J Gastroenterol. 17:1982;187-191.
2. Chapman R, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut. 24:1983;38-41.
3. Shepherd H, Selby W, Chapman R, Nolan D, Barbatis C, McGee J, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med. 52:1983;503-513.
4. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology. 13:1991;129-133.
5. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology. 16:1992;390-395.
6. Mehal W, Lo Y, Wordsworth B, Neuberger J, Hubscher S, Fleming K, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 106:1994;160-167.
7. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 108:1995;870-878.
8. Wilson A, Giovine Fd, Duff G. Genetics of TNFα in autoimmune, infectious and neoplastic diseases. J Inflamm. 45:1995;1-12.
9. Hill A. Genetics of infectious disease resistance. Curr Opin Genet Devel. 6:1996;348-353.
10. Pociot F, Molvig J, Wogensen L, Worsaae H, Dalboge H, Baek L, et al. A tumor necrosis factor beta polymorphism in relation to monokine secretion and insulin dependent diabetes mellitus. Scand J Immunol. 33:1991;37-49.
11. Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, Abbal M, et al. Association of tumor necrosis factor (TNF) and class II major histocompatability alleles with the secretion of TNF alpha and TNF beta by human mononuclear cells; a possible link to insulin dependent diabetes mellitus. Eur J Immunol. 23:1993;224-231.
12. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor alpha concentrations and oucome of patients with severe sepsis. Crit Care Med. 24:1996;381-384.
13. Wilson A, Symons J, McDowell T, McDevitt H, Duff G. Effects of a polymorphism in the human tumor necrosis factor a promotor on transcriptional activation. Proc Natl Acad Sci USA. 94:1997;3195-3199.
14. Cox A, Gonzalez A, Wilson A, Wilson R, Ward J, Artlet C, et al. Comparative analysis of the genetic associations of HLA-DR3 and tumor necrosis factor alpha with human IDDM. Diabetologia. 37:1994;500-503.
15. Bettinotti M, Hartung K, Deicher H, Messer G, Keller E, Weiss E, et al. Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosis: TNF-MHC haplotypes. Immunogenetics. 37:1993;449-454.
16. Chapman R, Arborgh B, Rhodes J, Summerfield J, Dick R, Scheur P, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut. 21:1980;870-877.
17. Weisner R, LaRusso N. Clinico-pathological features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 79:1980;200-206.
18. Strettell M, Donaldson P, Thompson L, Santrach P, Breanndan-Moore S, Williams R, et al. Allelic basis for HLA-encoded susceptability to type 1 autoimmune hepatitis. Gastroenterology. 112:1997;2028-2035.
19. Bunce M, Welsh K. Rapid DNA typing for HLA-C using sequence specific primers; identification of serologically and nonserologically defined C alleles including several new alleles. Tissue Antigens. 43:1994;7-17.
20. Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics. 39:1994;150-154.
21. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwjatowski D. Variation in the TNF-α promotor region associated with susceptibility to cerebral malaria. Nature. 371:1994;508-511.
22. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 19:1955;251-253.
23. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens. 43:1994;18-27.
24. Wilson A, Vries ND, Pociot F, Giovine FD, Putte LVD, Duff G. An allelic polymorphism within the human tumor necrosis factor alpha promotor region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med. 177:1993;557-560.
25. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med. 322:1990;1842-1844.
26. Opelz G, Mytilineous J, Scherer S, Dunkley H, Trejaut J, Chapman J, et al. For the collaborative transplant study. Survival of DNA HLA-DR typed and matched cadaver kidney transplants. Lancet. 338:1991;461-463.
27. Doherty D, Donaldson P. HLA-DRB and DQB typing by a combination of serology, restriction length polymorphism analysis and oligonucleotide probing. Eur J Immunogenet. 18:1991;111-118.
28. Stuber F, Udalova I, Book M, Drutskaya L, Kuprash D, Turetskaya R, et al. -308 tumor necrosis factor (TNF) is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm. 46:1996;42-50.
29. Bouma G, Crusius J, Pool MO, Kolkman J, Blomberg BV, Kostense P, et al. Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol. 43:1996;456-463.
30. Brinkman B, Zuijdgeest D, Kaijzel E, Breedveld F, Verweij C. Relevance of the tumor necrosis factor alpha (TNFα) -308 promotor polymorphism in TNFα gene regulation. J Inflamm. 46:1996;32-41.
31. Broome U, Erikson L, Sundin U, Sundqvist K. Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis. Scand J Gastroenterol. 27:1992;124-128.